Clinical Research Directory
Browse clinical research sites, groups, and studies.
Validation of the European Oncology Quality of Life Toolkit
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Summary
The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs. A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking. The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages. This is a multicentre observational study, with the following aims: * The primary aim is to perform the psychometric validation of the EUonQoL-Kit. * Secondary aims are to assess its acceptability, to validate the static and dynamic versions against each other, and to provide estimates of QoL across European countries. The EUonQoL-Kit will be administered to a sample of patients from 45 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,500 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire: * FACT-G (Functional Assessment of Cancer Therapy - General) and EQ-5D-5L (5-level European Quality of Life Five Dimension), to test concurrent validity. * Live-CAT version, to validate the static and dynamic versions against each other. * EUonQoL-Kit, at least 1 hour after the first completion, to assess test-retest reliability.
Official title: Validation of the European Oncology Quality of Life Toolkit. A European Pilot Survey.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
4000
Start Date
2024-08-31
Completion Date
2024-10-31
Last Updated
2024-08-20
Healthy Volunteers
No
Conditions
Interventions
Administration of the EUonQoL-Kit - Active Treatment questionnaire
Electronic questionnaire to be administered to patients in active treatment.
Administration of the EUonQoL-Kit - Survivors questionnaire
Electronic questionnaire to be administered to cancer survivors.
Administration of the EUonQoL-Kit - Palliative Care questionnaire
Electronic questionnaire to be administered to patients in palliative care.
Locations (45)
Mother Teresa University Hospital
Tirana, Albania
Comprehensive Cancer Center
Vienna, Austria
Kortrijk Kankercentrum AZ Groeninge
Kortrijk, Belgium
Bulgarian Joint Cancer Network
Varna, Bulgaria
Klinika za tumore Klinički bolnički centar Sestre milosrdnice
Zagreb, Croatia
Cyprus Association of Cancer Patients and Friends (PASYKAF)
Nicosia, Cyprus
Masarykův onkologický ústav
Brno, Czechia
Region Hovedstaden (Rigshospitalet)
Hillerød, Denmark
North Estonia Medical Centre
Tallinn, Estonia
Sihtasutus Tartu Ülikooli Kliinikum
Tartu, Estonia
HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala
Helsinki, Finland
lnstitut de Cancérologie de l'Ouest (ICO)
Angers, France
Institut Curie
Paris, France
Gustave Roussy
Villejuif, France
Petre Shotadze Tbilisi Medical Academy
Tbilisi, Georgia
Universitäres Centrum für Tumorerkrankungen (UCT)
Frankfurt, Germany
Deutsches Krebsforschungszentrum (DKFZ)
Heidelberg, Germany
Comprehensive Cancer Center Munich
Munich, Germany
General Oncology Hospital of Athens - Saint Savvas
Athens, Greece
Országos Onkológiai Intézet
Budapest, Hungary
Trinity St. James's Cancer Institute
Dublin, Ireland
Istituto Tumori Giovanni Paolo II, IRCCS
Bari, Italy
Istituto Europeo di Oncologia, IRCCS
Milan, Italy
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy
Istituto Nazionale Tumori Regina Elena
Roma, Italy
Riga East University Hospital
Riga, Latvia
National Cancer Institute
Vilnius, Lithuania
Oncologic Institute of Moldova
Chisinau, Moldova
Netherlands Cancer Institute
Amsterdam, Netherlands
Oslo University Hospital (OUS)
Oslo, Norway
Greater Poland Cancer Centre
Poznan, Poland
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy
Warsaw, Poland
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto)
Porto, Portugal
Institutul Oncologic "Al. Trestioreanu" (IOB)
Bucharest, Romania
The "Prof. Dr. Ion Chiricuta"Institute of Oncology (IOCN)
Cluj-Napoca, Romania
Oncology Institute of Vojvodina
Kamenitz, Serbia
National Cancer Institute (Národný onkologický ústav)
Bratislava, Slovakia
Onkološki Inštitut Ljubljana
Ljubljana, Slovenia
Vall Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Fundación Instituto Valenciano de Oncología (IVO)
Valencia, Spain
Sahlgrenska comprehensive cancer centre
Gothenburg, Sweden
Region Skåne - University Hospital Cancer Centre
Lund, Sweden
Anadolu Medical Center
Gebze, Turkey (Türkiye)
Turkey Cancer Institute
Istanbul, Turkey (Türkiye)
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom